Clinical trial
Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer…
NCT00038662 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00038662 |
|---|---|
| Title | Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure |
| Official title | A Phase 2 Study Evaluating the Safety and Efficacy of Atrasentan (ABT-627) in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | Atrasentan |
| Enrollment | 200 |
| Start date | May 1, 2002 |
| First posted | Jun 4, 2002 |
| Last update posted | Aug 15, 2006 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: